Takeda Pharmaceutical Co Ltd (TKPHF) cash flow statement

TKPHFOTCPharmaceutical PreparationsAlso trades as TAK

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026Score 5/30

$39.00+0.36 (+0.93%)

Close on Oct 19, 2026Market cap $134.41BP/E –Yield –

Takeda Pharmaceutical Co Ltd cash flow statement

AnnualQuarterlyTTM

JPY USD

Millions of JPY, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-03-31	FY 2019 2019-03-31	FY 2018 2018-03-31	FY 2017 2017-03-31
Depreciation & Amortization	721,127	761,396	728,002	664,400	583,151	559,671	583,649	247,691	182,127	171,426
Change in Inventory	-61,293	-34,973	-115,743	-79,155	-46,148	25,978	137,492	50,717	13,719	3,886
Operating Cash Flow	1,041,431	1,057,182	716,344	977,156	1,123,105	1,010,931	669,752	328,479	377,854	261,363
Capital Expenditures	-176,003	-200,795	-175,420	-140,657	-123,252	-111,206	-127,082	-77,677	-67,005	-61,660
Acquisitions	–	–	0	0	-49,672	0	-4,890	-2,958,686	-28,328	-589,144
Sale of Property, Plant & Equipment	6,454	78	8,606	962	1,815	46,453	12,578	50,717	2,965	2,629
Investing Cash Flow	-369,141	-367,060	-463,862	-607,102	-198,125	393,530	292,119	-2,835,698	-93,342	-655,691
Dividends Paid	-311,901	-302,498	-287,188	-279,416	-283,665	-283,357	-282,582	-142,952	-141,893	-141,688
Share Repurchases	-51,603	-51,860	-2,326	-26,929	-77,531	-2,141	-3,737	-1,172	-18,756	-23,117
Debt Issued	586,060	1,024,460	100,000	75,000	249,334	1,179,515	496,190	2,795,926	393,453	260,226
Debt Repaid	-200,432	-1,321,090	-320,901	-356,670	-810,115	-1,651,706	-701,057	0	-140,000	-191,763
Financing Cash Flow	-496,820	-751,425	-354,416	-709,148	-1,070,265	-1,088,354	-1,005,213	2,946,237	-326,226	289,896
Foreign Exchange Rate Adjustments	34,472	-11,385	26,204	22,929	28,758	12,501	-21,766	-31,269	4,565	5,742
Free Cash Flow	865,428	856,387	540,924	836,499	999,853	899,725	542,670	250,802	310,849	199,703

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2026

Gross margin: 65.1%
Operating margin: 0.1%
Net margin: -3.4%
Return on equity, FY2026: -2.1%

Financial strength

Current ratio: 1.09
Debt to equity: 0.66
Debt to assets: 31.5%
Cash to current liabilities: 21.0%

Valuation

P/E ratio: –
Price to sales: 4.68
Price to book: 2.84
Dividend yield: –